论文部分内容阅读
目的观察基质金属蛋白酶-9(MMP-9)及基质金属蛋白酶抑制因子-1(TIMP-1)在乳腺癌合并糖尿病癌组织及单纯乳腺癌癌组织中的表达。方法应用免疫组织化学方法检测单纯乳腺癌(单纯癌组)及乳腺癌合并糖尿病(糖癌组)癌组织石蜡标本中MMP-9和TIMP-1的表达变化。结果单纯乳腺癌及乳腺癌合并糖尿病癌组织中MMP-9及TIMP-1光密度值分别为0.300±0.015、0.466±0.023(P<0.01),0.332±0.018、0.264±0.013差异有统计学意义(P<0.01)。结论 MMP-9及TIMP-1参与了乳腺癌合并糖尿病的发生发展,可能是乳腺癌合并糖尿病预后不良的指标之一。
Objective To investigate the expression of matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-1 (TIMP-1) in breast cancer with or without primary breast cancer. Methods Immunohistochemistry was used to detect the expression of MMP-9 and TIMP-1 in paraffin-embedded specimens of simple breast cancer (simple carcinoma group) and breast cancer complicated with diabetes (carcinoma group). Results The optical density of MMP-9 and TIMP-1 in breast cancer and breast cancer with DM alone were 0.300 ± 0.015 and 0.466 ± 0.023 (P <0.01), 0.332 ± 0.018 and 0.264 ± 0.013, respectively P <0.01). Conclusion MMP-9 and TIMP-1 are involved in the occurrence and development of breast cancer with diabetes mellitus, which may be one of the indicators of poor prognosis in patients with breast cancer.